SERVIER
Servier today announced that the European Commission (EC) has approved the conversion of the conditional approval of PIXUVRI® (pixantrone) into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.
“There are limited treatment options for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma,” said Prof Pier Luigi Zinzani from the University of Bologna Institute of Hematology and Medical Oncology in Bologna, Italy. “PIXUVRI has demonstrated efficacy in late stage disease and the EC approval confirms PIXUVRI as a treatment option for these patients.”
The EC approval is based on data from the global clinical development of PIXUVRI.
The pivotal study, PIX301 was an open-label, randomized, Phase III study comparing PIXUVRI monotherapy with physician's choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab. PIXUVRI was shown to be beneficial in these patients: 20% of patients responded completely to PIXUVRI compared with 5.7% of patients receiving other agents (p=0.021).1,2
To satisfy requirements of the conditional authorization, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of PIXUVRI in patients that had received prior treatment regimens containing rituximab. In the study PIX306, all patients were previously treated with rituximab. While the superiority of PIXUVRI with rituximab compared to gemcitabine with rituximab was not met, both progression-free survival and overall survival results in patients with ≥ 2 prior treatment lines were similar, when indirectly compared to the PIXUVRI treated population in the pivotal study PIX301.2,3
“At Servier, we work diligently to develop and deliver medicines that address critical unmet medical needs in diseases such as multiply relapsed or refractory aggressive non-Hodgkin lymphoma,” said Patrick Therasse, Head of Servier Research and Development Oncology. “PIXUVRI has been benefitting patients since its conditional approval in 2012 but today’s decision brings reassurance to patients and clinicians that this medicine remains a relevant treatment option in this indication.”
The most common side effects with PIXUVRI are neutropenia, leukopenia, lymphopenia, anemia, thrombocytopenia, nausea, vomiting, skin discolouration, alopecia, chromaturia and asthenia.1
#ENDS#
About non-Hodgkin lymphoma (NHL)
NHL is a blood cancer that affects the lymphatic system, which is defined as a network of vessels and glands that run throughout the body.4 The lymphatic system is a key component of the immune system, as it plays a role in destroying old or abnormal cells and fighting bacteria and other infections.5
NHL can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.6 Around 168,000 new cases of NHL are diagnosed in the United States and Europe every year.
About PIXUVRI (pixantrone)
PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.7 PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.8
PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.9
More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu .
Servier commercializes PIXUVRI under a license from CTI BioPharma.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Find us on Social Media:
1 European Medicines Agency. Pixuvri SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf [last accessed May 2019].
2 Pettengell, R. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13: 696–706
3 Salles, G.A, et al. Results of a phase 3 randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation. American Society Hematology annual congress 2018. P4189.
4 NHS Conditions webpage. NHL Cancer. Available at http://www.nhs.uk/Conditions/non-hodgkins-lymphoma/Pages/Definition.aspx [last accessed May 2019].
5 Cancer Research UK. Lymphatic System. Available at http://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-lymphatic-system-and-cancer [last accessed May 2019].
6 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma [last accessed May 2019].
7 Pixuvri Summary of Product Characteristics, Available at: https://www.medicines.org.uk/emc/medicine/29829 [last accessed May 2019].
8 European Medicines Agency. Summary of the European public assessment report (EPAR) for Pixuvri. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri [last accessed May 2019].
9 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma [last accessed May 2019].
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005025/en/
Contact:
Servier Media Relations Sonia MARQUES: media@servier.com Tel.: +33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13
Jean-Clément VERGEAU: media@servier.com Tel.: +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Tech Services Market Slows in Q3, Despite Strong AI-Driven Cloud Demand: ISG Index™14.10.2025 10:00:00 CEST | Press release
Combined market up 5% in Q2, driven by 41% growth in cloud servicesManaged services slumps 25%, as companies remain cautious in the face of macro challenges Europe’s market for technology services and software slowed in the third quarter despite continuing strong demand for AI, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based as-a-service) rose 5 percent, to US $9.7 billion. Although the market has grown for seven consecutive quarters, averaging 14 percent quarterly growth during that span, the rate of growth in the third quarter was the lowest since the second quarter last year. “The market in Europe continues to be buoyed by strong, double-digit growth in cl
euNetworks Delivers New Fully Diverse Long Haul Network Route, Enabling Two Short Paths Connecting Frankfurt to Marseille and Milan14.10.2025 10:00:00 CEST | Press release
The shorter routes from Frankfurt to Marseille and Milan significantly reduce network latency for customers requiring diverse connectivity. The network enhances route diversity in the region, delivering new fibre routing for companies entering Europe via Marseille. euNetworks Group Limited (“euNetworks”), a European critical bandwidth infrastructure company, has today announced the completion of a new long haul fibre network route between Frankfurt and Zurich. This new network enables two short diverse paths between the many submarine cable landings along the Mediterranean coast, and the major data centre market of Frankfurt. The new route completes one of two fully diverse euNetworks long haul routes, with the option to either go via Milan and Zurich or via Marseille, Lyon and Geneva. euNetworks undertook this network investment to increase diversity options for its customers, enabling them to avoid points of failure where routes converge and cross, or otherwise take a long detour via
Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport14.10.2025 09:00:00 CEST | Press release
Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025. Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
Glesys to Acquire Verne’s Managed Private Cloud Operations and Two Data Centers in Finland14.10.2025 08:00:00 CEST | Press release
Verne, the leading provider of low-carbon high-performance data centers across the Nordics, has today announced that Glesys, a leading Nordic provider of cloud and IaaS services, will acquire Verne’s managed private cloud operations in Finland, including data center facilities in Pori and Tampere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006898290/en/ Pori Data Center Tunnel Corridor The agreement reflects both companies’ strategic priorities: for Glesys, it represents an important step in expanding its cloud and IaaS services, strengthening its position as a market leader in the Nordics and enhancing its capacity to deliver secure, energy-efficient and scalable solutions in the region. For Verne, it supports a sharpened focus on delivering low-carbon, high-performance colocation for AI and enterprise workloads, including its expansion plans in Mäntsälä, announced earlier this year. Glesys and Verne will continue to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom